Cardiovascular CRO

An experienced, global cardiovascular CRO

Cutting-edge cardiovascular science and novel therapies are bringing welcome relief to those suffering from heart disease and related disorders, while developers of drugs and medical devices are exploring a wide range of promising opportunities. Gene and RNA therapeutics, novel approaches to heart failure, precision medicine, cardiometabolic integration – these advances and many more are poised to revolutionize cardiac treatment.

That said, clinical trials present challenges unique to this therapeutic discipline. Cardiovascular trials often require thousands of patients across multiple sites and utilize multiple imaging modalities, functional assessments, biomarkers, and both clinical and patient-reported outcomes to detect meaningful differences in results. Many also involve years of follow-up to capture relevant endpoints, even as standards of care are concurrently evolving. Recruitment and retention of trial participants and coordinated site management with consistent data quality represent significant obstacles. 

Few clinical research organizations (CRO) offer the deep experience needed to help sponsors navigate these complexities. At the core of Parexel’s comprehensive solutions is a global network providing access to high-performing research sites across multiple regions. Underpinning this site network are recruitment analytics with predictive modeling to identify optimal sites and recruitment strategies, with refined inclusion/exclusion criteria to balance enrollment feasibility with scientific rigor. We address retention via patient-centric approaches that lighten the burden of participation.

Trials are designed and planned with scientific guidance from cardiovascular specialists and conducted by trial management teams with focused therapeutic expertise. Adjudication services represent another important strength, helping ensure the highest-quality data.

We have far-reaching experience in cardiovascular trials including heart failure, hypercholesterolemia, pulmonary hypertension, atherosclerosis and myocardial infarction, atrial fibrillation, deep vein thrombosis, dyslipidemia, and rare disease. Our current projects encompass the latest advances across the entire range of drugs and medical devices. These include gene and RNA therapies, mitochondrial enhancers, inflammation and immune modulation, and regenerative medicine, as well as leading-edge interventional approaches. We have extensive experience in specialized assessments including continuous hemodynamic monitoring and fingertip plethysmography.

Parexel's cardiovascular expertise is continuously evolving to match the pace of scientific innovation. Dedicated teams stay at the forefront of these advances to provide sponsors with informed guidance on trial design, endpoint selection, patient population targeting, and regulatory strategy for novel cardiovascular approaches. 

Our board-certified cardiologists, top-notch biostatisticians, and regulatory, product development, and market access specialists support the entire journey from concept to market approval efficiently and effectively.